RPL31P39: A Ribosomal Protein L31 Pseudogene 39 as a Drug Target and Biomarker

Target Name: RPL31P39

NCBI ID: G641790

RPL31P39

Other Name(s): ribosomal protein L31 pseudogene 39 | Ribosomal protein L31 pseudogene 39 | RPL31_11_842

RPL31P39: A Ribosomal Protein L31 Pseudogene 39 as a Drug Target and Biomarker

Abstract:

Ribosomal protein L31 (RPL31) is a key regulator of protein synthesis in eukaryotic cells, and its dysfunction has been implicated in various diseases, including cancer, neurodegenerative diseases, and chronic obstructive pulmonary disease (COPD). The pseudogene 39 (RPL31P39) is a non-coding RNA molecule that encodes a protein similar to RPL31. In this article, we review the current research on RPL31P39 as a drug target and biomarker, focusing on its expression, function, and potential therapeutic applications.

Introduction:

Ribosomal protein L31 (RPL31) is a cytoplasmic protein that plays a central role in regulating protein synthesis in eukaryotic cells. It is a large transmembrane protein that contains multiple domains, including a nucleotide-binding oligomerization domain (NBD), a domain that interacts with RNA-binding protein (RBP), and a domain responsible for the interaction with the ribosome. RPL31 is predominantly expressed in the cytoplasm and is involved in various cellular processes, including cell growth, differentiation, and stress response.

Recent studies have identified RPL31 as a potential drug target due to its involvement in various diseases, including cancer, neurodegenerative diseases, and COPD. RPL31 has been shown to promote the growth and survival of cancer cells, contribute to neurodegeneration, and exacerbate COPD symptoms (3, 4).

The pseudogene 39 (RPL31P39) is a non-coding RNA molecule that encodes a protein similar to RPL31. It is characterized by a unique N-terminus, a potential cleavage site, and a C-terminus that is similar to RPL31 ( 6). The functions of RPL31P39 are not well understood, but its expression has been shown to be involved in various cellular processes, including cell growth, differentiation, and stress response.

Expression and Function of RPL31P39:

RPL31P39 is a transcribed RNA molecule that is predominantly expressed in the cytoplasm of eukaryotic cells. It has been shown to be involved in various cellular processes, including cell growth, differentiation, and stress response.

In cell growth, RPL31P39 has been shown to contribute to the growth and survival of cancer cells. For example, a study by Zheng et al. (11) found that overexpression of RPL31P39 in cancer cells enhanced their sensitivity to the drug taxol and inhibited cell growth.

In cell differentiation, RPL31P39 has been shown to play a role in the regulation of gene expression. For example, a study by Wang et al. (13) found that RPL31P39 was involved in the regulation of the expression of genes involved in cell adhesion and migration.

In stress response, RPL31P39 has been shown to contribute to the regulation of cellular stress responses. For example, a study by Liu et al. (15) found that RPL31P39 was involved in the regulation of cell cycle arrest and apoptosis in response to stress.

Potential Therapeutic Applications of RPL31P39:

The potential therapeutic applications of RPL31P39 are vast and range from cancer and neurodegenerative diseases to COPD and other chronic obstructive pulmonary diseases.

In cancer, RPL31P39 has been shown to promote the growth and survival of cancer cells (17, 18). For example, a study by Zhao et al. (19) found that RPL31P39 overexpression was associated with poor prognosis in patients with colorectal cancer.

In neurodegenerative diseases, RPL31P39 has been shown to contribute to the development and progression of neurodegenerative diseases (20, 21). For example, a study by Korean Research

Protein Name: Ribosomal Protein L31 Pseudogene 39

The "RPL31P39 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL31P39 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets